Neo-epitopes/antigens discovery for cancer immunotherapy based treatment with precision oncology using advanced Artificial Intelligence
Session type: Proffered paper sessions
Cancer has historically been treated with surgery, radiation therapy, chemotherapy and hormone therapy, which use nonspecific mechanisms to attempt to remove or to kill cancer cells. More recently, a new class of immunotherapy known as checkpoint inhibitors is also being applied. However, the majority of patients do not respond to checkpoint inhibitors. We believe that neoantigen-targeted therapies may precisely direct the immune system to improve patient outcomes across both checkpoint-responsive and unresponsive disease. Early evidence shows that neoantigen-based vaccination can elicit T-cell responses and that neo-antigen targeted cell-therapy can cause tumor regression.
To make this happen we need accurate, fast, efficient, affordable neoantigens and corresponding T-cells with high specificity.
Identifying true tumor-specific neoantigens which are rare and unique that on the cell surface is like finding a needle in the haystack. To address this great challenge, CancerMoonshot developed a proprietary artificial intelligence platform called NeoAintigen leveraging huge extensive data from real human tumor samples. NeoAintigen AI platform was trained on a huge dataset and enables us to use sequence data from a cancer patient tumor biopsy to predict/identify exact mutations that will generate tumor-specific neoantigens supposed to on the tumor cell surface.
- Data-500+ patient samples, 1Million+ peptides, Various tumor types,HLA-Class1,CD4+ ,8-15 mer peptides
- Technology – AI, Deep learning, Machine learning, Inference engine, In-silico
- Identify at least one T-cell recognized neoepitope
- Average neo epitopes = 2
- Better predictive performance : 10-15 %
- Accuracy > 5x or 5 folds compared with publicly available approaches.
- Better targetable/correlation with T-cells
- Near real-time